The present invention relates to certain novel substituted dihydroimidazo[2,1-b]thiazole
and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds including pharmaceutically acceptable
salts thereof which have an affinity for 5-HT1A receptors and which
inhibit neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes
for their preparation, to pharmaceutical compositions containing them and to their
use in the treatment of depression, anxiety, psychoses including schizophrenia,
tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's
disease, obsessive-compulsive behaviour, panic attacks, social phobias, eating
disorders such as bulimia, anorexia, snaking and binge eating, non-insulin dependent
diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress, as an aid to smoking
cessation and in the treatment and/or prophylaxis of seizures, neurological disorders
such as epilepsy and/or in which there is neurological damage such as stroke, brain
trauma, cerebral ischaemia, head injuries and haemorrhage.
